What the FDA labels say about taking them together
Rifabutin and rilpivirine
Rifabutin's FDA label of September 1, 2026 names rilpivirine in its drug interactions section, and rilpivirine's label names rifabutin too. The rifabutin label: “Co-administration of rifabutin with Odefsey is not recommended, due to an expected decrease in tenofovir alafenamide in addition to the reported reduction in rilpivirine. …”
Check it at the source: the rifabutin FDA label on DailyMed (effective September 1, 2026, REMEDYREPACK INC.); the rilpivirine FDA label on DailyMed (effective August 28, 2025, Janssen Products, LP).
What does the rifabutin label say about rilpivirine?
Rifabutin label, drug interactionsCo-administered drug: Rilpivirine; Dosing regimen of co-administered drug: 25 mg once a day; Dosing regimen of rifabutin: 300 mg once a day; Study population (n): Healthy subjects (18); Effect on rifabutin: ND; Effect on co-administered drug: ↓ AUC by 42% ↓ C min by 48% ↓ C max by 31%; Recommendation: Co-administration of rifabutin with Odefsey (rilpivirine/tenofovir alafenamide/emtricitabine) is not recommended, due to an expected decrease in tenofovir alafenamide in addition to the reported reduction in rilpivirine. Refer to Odefsey prescribing information for additional information. …
Rifabutin label, warningsCo-administration with antiretroviral drugs metabolized by CYP3A, including but not limited to products containing bictegravir, elvitegravir, oral rilpivirine, or doravirine and anti-HCV drugs including but not limited to sofosbuvir (alone or in combination) may decrease plasma concentrations of those drugs, which may lead to loss of virologic response and possible development of resistance.
Source: FDA drug label (Rifabutin), NDA050689 (Pfizer), as published by REMEDYREPACK INC., effective September 1, 2026 (SPL set 25a60937-cbbe-4a50-994f-2ce15203f589), via openFDA; the full label on DailyMed
What does the rilpivirine label say about rifabutin?
Rilpivirine label, drug interactionsConcomitant Drug Class/Drug Name: Antimycobacterials: rifabutin The interaction between EDURANT and the drug was evaluated in a clinical study. All other drug-drug interactions shown are predicted.; Effect on Concentration of Rilpivirine or Concomitant Drug: ↓ rilpivirine; Clinical Comment: Concomitant use of EDURANT with rifabutin may cause a decrease in the plasma concentrations of rilpivirine (induction of CYP3A enzymes). Throughout coadministration of EDURANT with rifabutin, the EDURANT dose should be increased from 25 mg once daily to 50 mg once daily. When rifabutin coadministration is stopped, the EDURANT dose should be decreased to 25 mg once daily.
Source: FDA drug label (EDURANT), Janssen Products, LP, effective August 28, 2025 (SPL set 03880372-2c68-45c6-a53a-f420c49541d6), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rifabutin | Rilpivirine | |
|---|---|---|
| Labeled for | n/a | HIV |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $8.14 per capsule 150 mg capsule | $48.04 per tablet 25 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once